Platelet transfusion refractoriness doubles mortality risk in hematological patients, meta-analysis finds

Patients with blood disorders whose platelet counts fail to rise adequately after transfusion face roughly twice the mortality risk of patients who respond normally, according to a systematic review and meta-analysis published in BMC Cancer. The condition, known as platelet transfusion refractoriness, was linked to an approximately twofold increase in mortality risk across pooled cohort studies, with a hazard ratio of 2.09 (95% confidence interval: 1.77–2.47; P < 0.00001). The analysis was led by Xueya Han, Zhongyu Kang, Wei Liu and Daihong Li, and published open access on 22 October 2026.

It set out to quantitatively evaluate two questions that have divided the clinical literature: which characteristics are associated with the development of refractoriness, and what the condition means for long-term survival in patients with hematological diseases. Platelet transfusion refractoriness is described in the study as a frequent clinical challenge in hematological patients, driven by a complex interplay of immune and non-immune factors. Despite how often it is encountered in practice, its association with survival has been reported variably across previous studies, which the authors cite as the motivation for a quantitative synthesis rather than another single-center comparison.

Methodologically, the team conducted a systematic review and meta-analysis of cohort studies identified through comprehensive database searches. Risk factors for refractoriness were synthesized as odds ratios (OR) and survival outcomes, measured as overall survival, were synthesized as hazard ratios (HR), each with 95% confidence intervals. The evidence base comprised 22 cohort studies involving 7,479 patients with hematological diseases, of whom 1,440 experienced transfusion refractoriness.

The meta-analysis identified four clinical characteristics significantly associated with refractoriness. Female sex carried an odds ratio of 2.47 (95% CI: 1.42–4.29; P = 0.001), and fever an odds ratio of 2.20 (95% CI: 1.60–3.04; P < 0.00001). Both associations were statistically robust in the pooled estimates.

The remaining two factors showed even stronger pooled associations. Taken together, the authors characterize these factors as reflecting the complex interplay of immune and non-immune drivers behind the condition. Crucially, refractoriness was significantly associated with poor survival.

In the pooled analysis, patients with the condition faced an approximately twofold increase in mortality risk, with a hazard ratio of 2.09 (95% CI: 1.77–2.47; P < 0.00001). This survival penalty was the central prognostic finding of the review. Subgroup analysis confirmed that the survival penalty persisted across every clinical context the authors examined.

The pooled mortality risk estimate was 2.08 for patients assessed before hematopoietic stem cell transplantation (HSCT), 2.65 for patients assessed after transplantation, and 1.79 for patients who did not undergo transplantation. The authors note that the numerically highest pooled estimate appeared in the post-transplant subgroup, while stressing this as a numerical difference among pooled estimates rather than a definitive ranking of harm. On the basis of these findings, the study concludes that clinical management should prioritize the early identification of high-risk phenotypes, such as patients with splenomegaly or human leukocyte antigen (HLA) sensitization, in order to mitigate the adverse prognostic impact of refractoriness.

The strong antibody association in the pooled data aligns with the authors' emphasis on HLA sensitization as a marker of elevated risk. The findings come with the caveats inherent to the design. Because the analysis is limited to cohort studies, the reported hazard ratios and odds ratios represent associations rather than demonstrated causal effects.

With those limits, the review positions platelet transfusion refractoriness not merely as a transfusion-management problem but as a condition associated with substantially worse survival in hematological patients, and it frames early recognition of high-risk phenotypes as the practical priority for clinical teams.

Subject of Research: Prognostic impact and clinical risk factors of platelet transfusion refractoriness in hematological patients: a systematic review and meta-analysis of 7,479 cases

Article Title: Prognostic impact and clinical risk factors of platelet transfusion refractoriness in hematological patients: a systematic review and meta-analysis of 7,479 cases

Article References: Han, X., Kang, Z., Liu, W., & Li, D. (2026). Prognostic impact and clinical risk factors of platelet transfusion refractoriness in hematological patients: a systematic review and meta-analysis of 7,479 cases. BMC Cancer. https://doi.org/10.1186/s12885-026-17174-w

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17174-w

Keywords: Prognostic, impact, clinical, risk, factors, platelet, transfusion, refractoriness, hematological, patients, systematic, review